Weight Loss News

Diet Pill Rimonabant all Set to Confront FDA's scrutiny in Forthcoming Week

13 June 2007

The strong speculation whether the diet pill rimonabant would be able to make its way to the FDA approval for sale in the United States, is likely to be cleared out by the next week. Having waited for the FDA's decision, the Diet drug rimonabant, also distinguished as Acomplia, will finally face the moment of truth whilst the week ahead.

On June 12th, for the very first time, the FDA staff will demonstrate their views over the long-delayed diet pill.

And on the next subsequent day, i.e., June 13th, the Endocrinologic and Metabolic Drug Advisory Committee of the FDA, basically a group of outside specialists, will express diverse issues associated with Acomplia and its side-effects, and will cast vote on whether the drug to be recommended for the FDA approval or not.

Though the FDA is not obliged to act upon the suggestions of its advisory committees, which the agency usually considers, yet the fate of the drug extremely relies upon the permutation of both staff report and the advisory panel vote. The drug will be marketed with a novel name called Zimulti in the U.S.

If everything goes well, Zimulti could be available in the U.S market by early fall and while on the contrary, the FDA might require more trial data over the efficacy of the drug. Thereby the final verdict may impel the drug to stay away from the U.S. market.